Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.

Prevalence of statin intolerance: a meta-analysis

Open access

Abstract

Aims: Statin intolerance (SI) represents a significant public health problem for which precise estimates of prevalence are needed. Statin intolerance remains an important clinical challenge, and it is associated with an increased risk of cardiovascular events. This meta-analysis estimates the overall prevalence of SI, the prevalence according to different diagnostic criteria and in different disease settings, and identifies possible risk factors/conditions that might increase the risk of SI. Methods and results: We searched several databases up to 31 May 2021, for studies that reported the prevalence of SI. The primary endpoint was overall prevalence and prevalence according to a range of diagnostic criteria [National Lipid Association (NLA), International Lipid Expert Panel (ILEP), and European Atherosclerosis Society (EAS)] and in different disease settings. The secondary endpoint was to identify possible risk factors for SI. A random-effects model was applied to estimate the overall pooled prevalence. A total of 176 studies [112 randomized controlled trials (RCTs); 64 cohort studies] with 4 143 517 patients were ultimately included in the analysis. The overall prevalence of SI was 9.1% (95% confidence interval 8.0–10%). The prevalence was similar when defined using NLA, ILEP, and EAS criteria [7.0% (6.0–8.0%), 6.7% (5.0–8.0%), 5.9% (4.0–7.0%), respectively]. The prevalence of SI in RCTs was significantly lower compared with cohort studies [4.9% (4.0–6.0%) vs. 17% (14–19%)]. The prevalence of SI in studies including both primary and secondary prevention patients was much higher than when primary or secondary prevention patients were analysed separately [18% (14–21%), 8.2% (6.0–10%), 9.1% (6.0–11%), respectively]. Statin lipid solubility did not affect the prevalence of SI [4.0% (2.0–5.0%) vs. 5.0% (4.0–6.0%)]. Age [odds ratio (OR) 1.33, P = 0.04], female gender (OR 1.47, P = 0.007), Asian and Black race (P < 0.05 for both), obesity (OR 1.30, P = 0.02), diabetes mellitus (OR 1.26, P = 0.02), hypothyroidism (OR 1.37, P = 0.01), chronic liver, and renal failure (P < 0.05 for both) were significantly associated with SI in the meta-regression model. Antiarrhythmic agents, calcium channel blockers, alcohol use, and increased statin dose were also associated with a higher risk of SI. Conclusion: Based on the present analysis of >4 million patients, the prevalence of SI is low when diagnosed according to international definitions. These results support the concept that the prevalence of complete SI might often be overestimated and highlight the need for the careful assessment of patients with potential symptoms related to SI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehac015

Cites

210 of 210 references verified0 citation errors · 0 not checkable

Statistics

Figures

Structured Graphical Abstract The worldwide prevalence of statin intolerance and risk factors/conditions that effect or do not effect the risk of statin intolerance.
Structured Graphical Abstract The worldwide prevalence of statin intolerance and risk factors/conditions that effect or do not effect the risk of statin intolerance.CC BY · PubMed Central
Figure 1 The Preferred Reporting Items for Systematic Review and Meta-analysis flow-chart of studies included in the meta-analysis. Incomplete data: Studies that reported only statin discontinuation without specifying the reasons for discontinuation.
Figure 1 The Preferred Reporting Items for Systematic Review and Meta-analysis flow-chart of studies included in the meta-analysis. Incomplete data: Studies that reported only statin discontinuation without specifying the reasons for discontinuation.CC BY · PubMed Central
Figure 2 Prevalence of statin intolerance in primary prevention studies. Note: D–L random-effects model was used.
Figure 2 Prevalence of statin intolerance in primary prevention studies. Note: D–L random-effects model was used.CC BY · PubMed Central
Figure 3 Prevalence of statin intolerance in secondary prevention studies. Note: D–L random-effects model was used.
Figure 3 Prevalence of statin intolerance in secondary prevention studies. Note: D–L random-effects model was used.CC BY · PubMed Central
Figure 4 Prevalence of statin intolerance in combined primary and secondary prevention studies. Note: D–L random-effects model was used.
Figure 4 Prevalence of statin intolerance in combined primary and secondary prevention studies. Note: D–L random-effects model was used.CC BY · PubMed Central
Figure 5 Prevalence of statin intolerance—summary figure. NLA, National Lipid Association; ILEP, International Lipid Expert Panel; EAS, European Atherosclerosis Society; RCTs, randomized controlled trials; DM, diabetes mellitus; sCAD, stable coronary artery disease; ASC, acute coronary syndrome; MI, myocardial infarction; TIA, transient ischaemic attack; SI, statin intolerance.
Figure 5 Prevalence of statin intolerance—summary figure. NLA, National Lipid Association; ILEP, International Lipid Expert Panel; EAS, European Atherosclerosis Society; RCTs, randomized controlled trials; DM, diabetes mellitus; sCAD, stable coronary artery disease; ASC, acute coronary syndrome; MI, myocardial infarction; TIA, transient ischaemic attack; SI, statin intolerance.CC BY · PubMed Central
Figure 6 Summary meta-regression of (A) demographic and (B) risk factors and drugs with statin intolerance. SI, statin intolerance; BMI, body mass index; CLD, chronic liver disease; CRF, chronic renal failure; CCB, calcium channel blockers.
Figure 6 Summary meta-regression of (A) demographic and (B) risk factors and drugs with statin intolerance. SI, statin intolerance; BMI, body mass index; CLD, chronic liver disease; CRF, chronic renal failure; CCB, calcium channel blockers.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 210 references

Research works printed but not linked: 3

  1. Higgins, 2021, Cochrane Handbook for Systematic Reviews of Interventions version 6.2
  2. Howell, 2004, Compliance with statins in primary care, Pharm J, 272, 23
  3. Adverse Drug Reactions Advisory Committee (ADRAC), 2004, Risk factors for myopathy and rhabdomyolysis with the statins, Aust Adv Drug Reactions Bull, 23, 1

Cited by

See all 481

Metadata

Authors
Bytyçi, I., Penson, P. E., Mikhailidis, D. P., Wong, N. D., Hernandez, A. V., Sahebkar, A., Thompson, P. D., Mazidi, M., Rysz, J., Pella, D., Reiner, Ž., Toth, P. P., & Banach, M.
Affiliations
  • University Clinical Center of Kosovo (XK)
  • Liverpool John Moores University (GB)
  • The Royal Free Hospital (GB)
  • University of California, Irvine (US)
  • Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, University of Connecticut School of Pharmacy , Storrs, CT , USA
  • Mashhad University of Medical Sciences (IR)
  • Hartford Hospital (US)
  • King's College London (GB)
  • Medical University of Lodz (PL)
  • University of Pavol Jozef Šafárik (SK)
  • University Hospital Centre Zagreb (HR)
  • Johns Hopkins University (US)
Corresponding author
Banach, Maciej
Venue
European Heart Journal
Published
2022-02-16
Volume
43
Issue
34
Pages
3213-3223
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W4206276470
Cited by
481
References
210
Citations by year
2026: 93 · 2025: 108 · 2024: 132 · 2023: 100 · 2022: 46
FWCI
22.93
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Liverpool John Moores University (acceptedVersion)
  • KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
statin intolerance, prevalence, statin adverse effects, diagnostic criteria, risk factors, primary and secondary prevention, obesity, diabetes mellitus, age and sex differences, cardiovascular risk, lipid-lowering therapy, statin-induced myopathy, rhabdomyolysis, hyperglycemia, hypokalemia, hypomagnesemia
MeSH terms
Female, Humans, Lipids, Male, Risk Factors, Prevalence, Randomized Controlled Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevalence of statin intolerance: a meta-analysis. https://app.cochat.ai/papers/10.1093/eurheartj/ehac015
The paper
Bytyçi, I., Penson, P. E., Mikhailidis, D. P., Wong, N. D., Hernandez, A. V., Sahebkar, A., Thompson, P. D., Mazidi, M., Rysz, J., Pella, D., Reiner, Ž., Toth, P. P., & Banach, M. (2022). Prevalence of statin intolerance: a meta-analysis. European Heart Journal. https://doi.org/10.1093/eurheartj/ehac015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.